z-logo
open-access-imgOpen Access
Substance Use and Mental Health Outcomes for Comorbid Patients in Psychiatric Day Treatment
Author(s) -
Stephen Magura,
Andrew Rosenblum,
Thomas Betzler
Publication year - 2009
Publication title -
substance abuse research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.027
H-Index - 22
ISSN - 1178-2218
DOI - 10.4137/sart.s3462
Subject(s) - medicine , psychiatry , drug , mental health , mood , depression (economics) , quality of life (healthcare) , schizoaffective disorder , bipolar disorder , distress , schizophrenia (object oriented programming) , clinical psychology , psychosis , nursing , economics , macroeconomics
The study's purpose was to determine treatment outcomes for patients who present with drug use vs. those presenting with no drug use at admission to a psychiatric day treatment program. Consecutively admitted patients completed confidential interviews which included psychological distress and quality of life measures and provided urine specimens for toxicology at admission and six month follow-up. Subjects positive by past 30 day self-report or urinalysis were categorized as drug users. Major psychiatric diagnoses were: major depression 25%; bipolar, 13%; other mood 13%; schizoaffective 13%; schizophrenia 13%. Drug use at admission was: cocaine 35%; marijuana 33%; opiates 18%, (meth)amphetamines, 6% For each of these drugs, the percentage of patients positive at admission who remitted from using the drug significantly exceeded the percentage negative at baseline who initiated using the drug. Overall, there were significant decreases in psychological distress and significant improvement on quality of life, but no change on positive affect. There were no significant differences between drug users and non-drug users on symptom reduction and improvement in quality of life. Psychiatric day treatment appears to benefit comorbid patients by reducing the net number of patients who actively use certain common drugs and by improving psychological status and quality of life to the same degree as for non-drug using patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom